AUPH - Aurinia Pharmaceuticals Inc logo

AUPH

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals develops and commercializes therapies for autoimmune diseases. Its primary product, LUPKYNIS, is an oral treatment for active lupus nephritis, while also working on aritinercept for other autoimmune conditions.

⚕️ Healthcare NASDAQ Listed 1999 $ USD
$1,000 invested 20 years ago$10,131today

Score Overview

1 Year
Score7.1
Net Growth3.83%
Net TrendGrew
Net Income Consistency
Rev Growth5.38%
Rev TrendGrew
Revenue Consistency
5 Years
Score9.3
Net Growth264.79%
Net TrendEvery year
Net Income Consistency
Rev Growth5x
Rev TrendEvery year
Revenue Consistency
10 Years
Score6.6
Net Growth13x
Net Trend60%
Net Income ConsistencyInconsistent
Rev Growth1723x
Rev Trend80%
Revenue Consistency80%
20 Years
Score5.9
Net Growth14x
Net Trend55%
Net Income ConsistencyInconsistent
Rev Growth83x
Rev Trend55%
Revenue Consistency40%
All Time
Score4.6
Net Growth244x
Net Trend48%
Net Income ConsistencyInconsistent
Rev Growth218x
Rev Trend52%
Revenue Consistency23%

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-05-21
$ 15.45
1 Year2025-05-21
$ 8.3485.25%
5 Years2021-05-21
$ 13.0418.48%
10 Years2016-05-20
$ 2.485x
20 Years2006-05-18
$ 1.529x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 298M$ 298M$ 378M
2025$ 283M$ 287M$ 397M
2024$ 235M$ 5M$ 358M
2023$ 175M-$ 78M$ 350M
2022$ 134M-$ 108M$ 389M
2021$ 45M-$ 180M$ 466M
2020$ 50M-$ 102M$ 398M
2019$ 318K-$ 88M$ 306M
2018$ 463K-$ 64M$ 125M
2017$ 420K-$ 70M$ 173M
2016$ 173K-$ 23M$ 39M
2015$ 235K-$ 18M$ 15M
2014$ 278K-$ 16M$ 32M
2013$ 948.56K-$ 2M$ 1M
2012$ 6M-$ 9M$ 184.96K
2011$ 927.52K-$ 2M$ 5M
2010$ 3M-$ 3M$ 6M
2009$ 4M-$ 7M$ 4M
2008$ 3M-$ 15M$ 21M
2007$ 2M-$ 33M$ 32M
2006$ 3M-$ 22M$ 22M
2005$ 1M-$ 29M$ 45M
2004$ 1M-$ 22M$ 50M
2003$ 7M-$ 14M$ 62M
2002$ 11M-$ 365.87K$ 40M
2001$ 5M-$ 7M$ 33M
2000$ 902.77K-$ 6M$ 11M
IPO1999$ 1M-$ 1M$ 2M